Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
暂无分享,去创建一个
M. Ancukiewicz | B. Czito | E. di Tomaso | Rekha Samuel | P. Shellito | Lei Xu | Jeffrey W Clark | Rakesh K Jain | D. Duda | Daniel C Chung | Gregory Y Lauwers | Pei-Chun Lin | Martin Poleski | Rex Bentley | Christopher G. Willett
[1] Jeffrey W. Clark,et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Marek Ancukiewicz,et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Dushyant V. Sahani,et al. Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.
[4] M. Neurath,et al. Cytokines in colitis associated cancer: potential drug targets? , 2008, Inflammation & allergy drug targets.
[5] D. Hanahan,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[6] R. Geffers,et al. Gene Expression Profiling of Human Decidual Macrophages: Evidence for Immunosuppressive Phenotype , 2008, PloS one.
[7] M. Menger,et al. Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. , 2007, Neoplasia.
[8] Franklin Peale,et al. Neuropilin-1 Binds to VEGF121 and Regulates Endothelial Cell Migration and Sprouting* , 2007, Journal of Biological Chemistry.
[9] A. Grothey. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. , 2006, Seminars in oncology.
[10] Ricky T. Tong,et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Brand,et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. , 2005, Experimental cell research.
[12] T. Tsuruo,et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. , 2005, Cancer research.
[13] G. Opdenakker,et al. GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. , 2005, Experimental cell research.
[14] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[15] L. Ellis,et al. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. , 2004, The American journal of pathology.
[16] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[17] H. Yoshiji,et al. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. , 1997, Cancer research.
[18] N. Wolmark,et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[20] J. Pollard. Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.